SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rise is being tied mainly to Morgan Stanley naming it a top pick, with traders highlighting AWS growth and AI opportunities such as Trainium, Bedrock and agentic commerce. Many are bullish on the rally, while others question whether it will last and point to heavy AI spending and uncertain returns as risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide toward fresh lows, with bearish traders citing possible continued dilution, upcoming filings, and doubts about Truth Socials engagement and business prospects. Political backlash over Trumps policies and midterm prospects dominates the broader debate, while some traders view the decline as a buying opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention amid a sharp selloff as competing wet-AMD trial results shake confidence in retinal TKI therapies and raise questions about AXPAXLIs differentiation and commercial prospects. Traders disagree on whether competitor setbacks and Oculars positive SOL-1 results strengthen its position or whether lingering clinical and regulatory uncertainty outweighs its planned NDA filing.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is under pressure amid repeated analyst price-target cuts tied to soft residential roofing demand, a prolonged housing recovery, and higher costs, extending a steep slide toward new lows. Traders are divided between frustration over the selloff and managements limited communication, and long-term optimism about the acquisition strategy and eventual integration gains.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, addressing the FDAs earlier efficacy concerns; the company plans to resubmit its application. Traders are broadly positive on the results but debate the remaining regulatory path and dizziness reports, while others point to profit-taking and possible short-covering as the stock trades volatile.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent insider share purchases by the CEO and directors have fueled hopes of a rebound, with traders watching for a sustained move above a key technical level. Skeptics point to weakness in the core Celsius brand and say speculation about a Pepsi buyout is unconfirmed.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after an earnings-driven rally, with traders pointing to a return to profitability and strong year-over-year revenue growth amid demand for InP substrates used in AI data-center optics. Bulls see room for growth, while skeptics argue the valuation is stretched and the stock remains highly volatile.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformance versus Bitcoin are driving attention, with traders pointing to doubts about its AI/data-center pivot and the lack of signed tenant leases alongside criticism of management and shareholder dilution. Some are buying the sharp dip or anticipating a short squeeze, but bearish traders see continued downside absent a contract or stronger Bitcoin-linked gains.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERSs sharp rally and breakout above its prior high are fueling takeover speculation, especially chatter about Lundbeck and a possible bidding war, though no deal is confirmed and some traders doubt the rumors. Others point to revenue growth and the XP-8121 pipeline as support for the companys prospects independent of a sale.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its quarterly results, with traders focused on margins and profitability despite strong deliveries; bullish bets on the recent rally and an earnings move contrast with bearish expectations of a miss. The Roadster reveal has also fueled speculative SpaceX-merger chatter, though traders disagree about its business significance and whether a deal is likely.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Equity

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication 

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corp.

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.</li><li>RGEN stock gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.</li><li>BIIB stock gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;</li></ul>Shares of pharmaceutical companies Kodiak Sciences Inc. (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.&nbsp;<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.<a href="https://stocktwits.com/symbol/RGEN">RGEN stock</a> gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;<h2 class="st-heading-2">Kodiak Sciences Makes It To September’s Top Five Biotech Gainers</h2><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock jumped to a 52-week high of $95.77 on Monday, its steepest climb on record, after the company scored a major drug win.&nbsp;Kodiak&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kod-stock-september-top-5-biotech-gainers-eye-drug-shkreli-still-sucks/cZMmZ2VRBXj">said</a> Monday that its two experimental therapies, Zenkuda and KSI-501, met the primary endpoints in the Phase 3 Daybreak trial, with both delivering vision improvements that were non-inferior to those seen with 2-mg aflibercept, the active ingredient in Regeneron’s original Eylea.&nbsp;The company reported no cases of intraocular inflammation in the Zenkuda arm and plans to seek regulatory approval in the fourth quarter, supported by positive data from five Phase 3 studies spanning three eye diseases.&nbsp;KSI-501, also known as Tabirafusp-ted, uses a different mechanism, and Kodiak plans additional analyses to determine whether certain wet AMD patients could benefit from its IL-6-targeting component. A separate Phase 3 study is evaluating KSI-501 in diabetic macular edema.On Stocktwits, retail sentiment around <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock was ‘extremely bullish’ at the time of writing. The company's shares have rallied more than 245% in 2026.&nbsp;<h2 class="st-heading-2">Repligen Extends Gains From Strong Quarter 2026&nbsp;</h2>RGEN stock climbed to a 52-week high of $198.87 on Monday, putting it on track for a sixth straight month of gains amid strong earnings, higher full-year guidance, and a major expansion into cell therapy.The company reported Q2 revenue of $204.1 million, up about 12% year over year, while adjusted earnings per share of $0.54 exceeded analyst expectations. Management subsequently raised its 2026 organic revenue-growth outlook to 10.5%-13.5% and increased adjusted EPS guidance to $2.03-$2.09.&nbsp;Repligen also recently agreed to acquire BioLife Solutions for approximately $1.5 billion, expanding its portfolio into cell-therapy biopreservation and strengthening its position in the growing cell and gene therapy market. The transaction is expected to broaden Repligen’s addressable market and add complementary products and capabilities.&nbsp;On Stocktwits, retail sentiment around RGEN stock was ‘bullish’ at the time of writing. The company's shares are up more than 18% this year.&nbsp;<h2 class="st-heading-2">Biogen Rises On The Back Of Strong Earnings, Positive Product Pipeline Updates</h2>BIIB stock rose to an annual high of $230.49 on Monday, putting it on track for a second consecutive month of gains as investors responded to strong second-quarter 2026 results, accelerating growth across its newer products and a series of pipeline and strategic developments.&nbsp;The company’s growth portfolio generated $1.06 billion in Q2 revenue, up 24% year-over-year, driven by continued launches and sales momentum for Skyclarys, Qalsody, Zurzuvae and Leqembi.Biogen also reported several pipeline catalysts. Leqembi received approval in Japan for a more convenient pen-based, at-home administration and a new formulation, Leqembi Iqlik.&nbsp;The company agreed to acquire RayThera for about $1 billion, strengthening its immunology portfolio, while Salanersen received FDA Breakthrough Therapy designation for spinal muscular atrophy.&nbsp;Biogen also highlighted encouraging clinical data for Zorevunersen in Dravet syndrome.On Stocktwits, retail sentiment around BIIB stock was ‘neutral’ at the time of writing. The company's shares have gained more than 28% in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biogen Inc

Kodiak Sciences Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGEN Repligen Corp.

Fundamentals

Latest RGEN News